FDA approval weighs advantages, harms of the Alzheimer’s drug lecanemab

Federal drug regulators will determine by July 6 whether or not to grant the primary conventional approval to an amyloid-busting drug to deal with Alzheimer’s illness.

On June 9, the Meals and Drug Administration’s advisory panel of specialists endorsed the drug, lecanemab, as efficient – whereas not voting on the thornier query of the right way to advise medical doctors and sufferers about identified unwanted effects and medical dangers. The FDA does not have to just accept its advisory panel’s advice when evaluating a drug however usually does.